Trial Profile
Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Advanced or Metastatic Breast Cancer. A Study of the Cancer Institute of New Jersey Oncology Group (CINJOG).
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 19 Sep 2023
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions
- 18 Feb 2017 Status changed from recruiting to discontinued.
- 21 May 2015 Planned End Date changed from 1 Jun 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov record.
- 21 May 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov record.